SWOG clinical trial number
CTSU/EA2176
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
Closed
Phase
Abbreviated Title
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
Activated
10/15/2020
Closed
09/23/2024
Research committees
Gastrointestinal Cancer
Treatment
Carboplatin
Nivolumab
Paclitaxel
Eligibility Criteria Expand/Collapse
SWOG is participating in this study through the Cancer Trials Support Unity (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.
Publication Information Expand/Collapse
Other Clinical Trials
SWOG Clinical Trial Number
S2433
Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma
Research Committee(s)
Gastrointestinal Cancer
Activated
12/26/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2303
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Accrual
35%
Open
Phase
SWOG Clinical Trial Number
CTSU/A022101
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase